Novavax (NVAX) says that it sees a pathway to resolving issues with the FDA for full approval of its Covid vaccine shot, Reuters’ Sriparna Roy reports. The company believes commitments to run new trials will be after it receives approval for the shot, saying “Based on what we’ve received to date, formally from FDA, they’re asking for a post-marketing commitment.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Unusually active option classes on open May 8th
- Novavax reports Q1 EPS $2.93, consensus 71c
- Novavax raises 2025 adjusted revenue view to $975M-$1.025B from $300M-$350M
- NVAX Earnings: Novavax Stock Soars 33% in Pre-Market on Explosive Q1 Profit
- Can Novavax’s Q1 Earnings Spark a Comeback for NVAX Stock?